Alzheimer's Disease VEGF/Angiogenic Signaling and Cerebral Blood Flow Therapy Companies

Overview

VEGF (vascular endothelial growth factor) signaling and angiogenic approaches represent a compelling therapeutic strategy for Alzheimer's disease by targeting the neurovascular unit dysfunction that underlies disease progression. In AD, cerebral blood flow (CBF) reductions precede cognitive symptoms by years, and VEGF pathway impairment contributes to both vascular and neuronal pathology.

This category page covers companies developing:

• VEGF/VEGFR agonists — direct VEGF pathway activation for neurotrophic and angiogenic effects
• Angiogenesis modulators — compounds promoting new blood vessel formation in the brain
• Cerebral blood flow enhancers — vasodilators, NO donors, and CBF restoration approaches
• Neurovascular coupling restorers — therapies targeting the signaling between neurons and blood vessels
• VEGF mimetics and neurotrophin fusions — engineered proteins combining VEGF with neurotrophic signaling

The field builds on evidence that VEGF acts as a neurotrophic factor for hippocampal and cortical neurons, not merely an angiogenic cytokine. VEGF receptor 2 (VEGFR2/KDR) is expressed on neurons, and its activation promotes PI3K/Akt and MAPK/ERK survival signaling while simultaneously supporting vascular health[@vegf2023][@vegf2024].

Key Companies

Athira Pharma

Athira Pharma (NASDAQ: ATHA) is developing fosgonimeton (ATH-1017), a small molecule HGF/MET receptor activator with downstream neurotrophic and angiogenic effects relevant to AD.

...

Overview

VEGF (vascular endothelial growth factor) signaling and angiogenic approaches represent a compelling therapeutic strategy for Alzheimer's disease by targeting the neurovascular unit dysfunction that underlies disease progression. In AD, cerebral blood flow (CBF) reductions precede cognitive symptoms by years, and VEGF pathway impairment contributes to both vascular and neuronal pathology.

This category page covers companies developing:

• VEGF/VEGFR agonists — direct VEGF pathway activation for neurotrophic and angiogenic effects
• Angiogenesis modulators — compounds promoting new blood vessel formation in the brain
• Cerebral blood flow enhancers — vasodilators, NO donors, and CBF restoration approaches
• Neurovascular coupling restorers — therapies targeting the signaling between neurons and blood vessels
• VEGF mimetics and neurotrophin fusions — engineered proteins combining VEGF with neurotrophic signaling

The field builds on evidence that VEGF acts as a neurotrophic factor for hippocampal and cortical neurons, not merely an angiogenic cytokine. VEGF receptor 2 (VEGFR2/KDR) is expressed on neurons, and its activation promotes PI3K/Akt and MAPK/ERK survival signaling while simultaneously supporting vascular health[@vegf2023][@vegf2024].

Key Companies

Athira Pharma

Athira Pharma (NASDAQ: ATHA) is developing fosgonimeton (ATH-1017), a small molecule HGF/MET receptor activator with downstream neurotrophic and angiogenic effects relevant to AD.

| Attribute | Details |
|-----------|---------|
| Focus | HGF/MET activation → neurovascular enhancement |
| Lead Candidate | Fosgonimeton (ATH-1017) |
| Indication | Alzheimer's disease |
| Stage | Phase 2/3 (ACT-AD study) |
| Mechanism | HGF/MET receptor agonist |

Scientific Rationale: The HGF/MET system shares downstream signaling with VEGF pathways (PI3K/Akt, MAPK/ERK) and promotes angiogenesis, neuroprotection, and improved cerebral blood flow. Activation of MET receptors on both neurons and endothelial cells provides dual neurovascular benefit[@bdnf2023].

Clinical Development:

• Phase 2 LIFT-AD study (completed): showed signals of cognitive improvement
• Phase 2/3 ACT-AD confirmatory study (recruiting)
• Oral administration, brain-penetrant
• No ARIA risk (unlike anti-amyloid antibodies)

Key Advantages: Small molecule oral drug, addresses both neurotrophic and vascular components of AD, disease-modifying potential.

4D Molecular Therapeutics (4DMT)

4D Molecular Therapeutics (NASDAQ: FDMT) is developing 4D-150, a dual VEGF/brain-derived neurotrophic factor (BDNF) vector using its proprietary R100 capsid for intravitreal delivery, with applications extending to CNS angiogenic modulation[@bdnf2023].

| Attribute | Details |
|-----------|---------|
| Focus | VEGF/BDNF co-expression gene therapy |
| Platform | R100 capsid (intravitreal delivery) |
| Indication | Wet AMD, with CNS applications in development |
| Stage | Phase 2 (eye); CNS preclinical |

Notes: While 4D-150 is primarily developed for wet age-related macular degeneration (wet AMD), the company's VEGF/BDNF combination approach has potential AD applications through local CNS delivery strategies. The R100 capsid enables high-efficiency gene delivery to neural tissues.

Roche / Genentech

Roche and Genentech have explored VEGF pathway modulation in AD through anti-amyloid approaches with indirect neurovascular effects:

| Attribute | Details |
|-----------|---------|
| Focus | Anti-Aβ antibodies with neurovascular benefit |
| Lead Candidates | Gantenerumab, Crenezumab |
| Indication | Alzheimer's disease |
| Stage | Phase 3 (DIAN-TU, SKYPOOL) |
| Mechanism | Aβ plaque reduction → reduced CAA → improved CBF |

Scientific Rationale: By clearing amyloid plaques and vascular amyloid (CAA), anti-Aβ antibodies reduce the amyloid burden on cerebral vessels, potentially restoring cerebral blood flow. Gantenerumab in particular has shown dose-dependent CAA reduction in the SCarlet Roads trial[@cerebral2022].

Asahi Kasei

Asahi Kasei, a Japanese conglomerate, has research programs in VEGF receptor modulation for CNS applications:

| Attribute | Details |
|-----------|---------|
| Focus | VEGFR modulators for neurodegeneration |
| Stage | Discovery |
| Region | Japan |
| Notes | Research collaboration with academic institutions |

Takeda Pharmaceutical

Takeda maintains broad neurodegeneration research programs including neurovascular restoration approaches:

| Attribute | Details |
|-----------|---------|
| Focus | Neurovascular unit restoration |
| Stage | Discovery/preclinical |
| Notes | Broad CNS portfolio includes angiogenic research |

Cerevance

Cerevance is developing CVN231, a compound targeting neural circuit stabilization with neurovascular effects:

| Attribute | Details |
|-----------|---------|
| Focus | Neural circuit and neurovascular enhancement |
| Platform | Nuclear receptor modulation |
| Indication | Alzheimer's disease, Parkinson's disease |
| Stage | Preclinical |

Other Companies in VEGF/Angiogenesis Space

| Company | Mechanism | Stage | Notes |
|---------|-----------|-------|-------|
| AbbVie | VEGF pathway modulators | Discovery | Broad neurodegeneration research |
| Biocon | VEGF biosimilar programs | Preclinical | Indian biotech, CNS focus |
| Dompé | Neurotrophin analogs | Research | Italian biotech, neurotrophic focus |
| Cellectricon | VEGF screening platform | Research | Contract research for VEGF pathway |
| Oryzon Genomics | Epigenetic modulators (LSD1) with angiogenic effects | Phase 1 | CNS indications |

Therapeutic Targets

1. VEGF/VEGFR2 Pathway

Direct activation of VEGF signaling for dual neurovascular benefit:

| Target | Approach | Companies |
|--------|----------|------------|
| VEGFR2 activation | VEGFR2 agonists, VEGF mimetics | Asahi Kasei (research) |
| VEGF expression | Gene therapy, AAV delivery | 4DMT (exploratory) |
| VEGFR downstream | HGF/MET activators (shared pathway) | Athira Pharma |
| VEGF-B signaling | VEGFR1/Flt1 modulation | Research |

2. Cerebral Blood Flow (CBF) Enhancement

Direct approaches to restore cerebral perfusion:

| Target | Approach | Companies |
|--------|----------|------------|
| Neurovascular coupling | NO signaling modulators | Multiple programs |
| Endothelial function | LRP1 activators | Research |
| Vasodilation | PDE inhibitors, NO donors | Research |
| Microvascular density | Angiogenic growth factors | Research |
| Pericyte function | PDGF-BB agonists | Preclinical |

3. Angiogenesis Restoration

Promoting new blood vessel formation in the brain:

| Target | Approach | Companies |
|--------|----------|------------|
| Angiogenic signaling | VEGF, FGF, HGF delivery | Multiple programs |
| Endothelial progenitor cells | Cell therapy approaches | Research |
| Angiogenic switch | HIF prolyl hydroxylase inhibitors | Research |
| VEGF isoform optimization | VEGF-Axxx/bxxx modulation | Research |

4. Neurovascular Unit Support

Comprehensive targeting of the neurovascular unit:

| Target | Approach | Companies |
|--------|----------|------------|
| Neurovascular coupling | Neural-vascular signaling modulators | Cerevance |
| BBB restoration | Tight junction enhancers | Research |
| Pericyte coverage | PDGF-BB signaling | Preclinical |
| Astrocyte function | AQP4 polarization | Research |

Mechanism of Action

VEGF Signaling in Alzheimer's Disease

Cerebral Blood Flow Dysfunction in AD

Reduced cerebral blood flow is an early and progressive feature of AD:

Early marker: CBF reductions precede cognitive symptoms by years[@cbf2023]

Hippocampal vulnerability: The hippocampus shows early and pronounced hypoperfusion

Amyloid relationship: Aβ deposition in vessel walls (CAA) directly impairs CBF

Neurovascular uncoupling: Neuronal activity no longer properly regulates local blood flow

Endothelial dysfunction: Reduced NO bioavailability and impaired vasodilation

VEGF as Neurotrophic Factor

Beyond its canonical angiogenic role, VEGF acts as a neurotrophic factor for hippocampal and cortical neurons[@vegf2023][@nonangiogenic2022]:

• Direct neuronal survival: VEGFR2 on neurons activates PI3K/Akt anti-apoptotic signaling
• Synaptic plasticity: VEGF promotes hippocampal long-term potentiation (LTP)
• Neurogenesis: VEGF supports survival and differentiation of neural progenitors
• Anti-inflammatory: VEGFR2 activation reduces microglial activation
• Memory enhancement: VEGF levels correlate with memory performance in animal models

Angiogenesis and Neuroprotection

The coupling between angiogenesis and neuroprotection enables dual benefits:

New blood vessel formation improves delivery of oxygen and glucose to vulnerable neurons

Restored neurovascular coupling links neural activity to blood flow

BBB support prevents infiltration of peripheral neurotoxic factors

Synergy with amyloid clearance — improved CBF enhances glymphatic Aβ clearance

Scientific Rationale

VEGF Expression Changes in AD

Multiple studies document VEGF pathway alterations in AD brains[@vegf2022b][@vegfbased2022]:

• Altered VEGF levels: Some studies report increased VEGF (compensatory), others report decreased VEGF (dysfunctional)
• VEGFR2 downregulation: Neuronal VEGFR2 expression is reduced in AD hippocampus
• Angiogenic imbalance: VEGF/VEGF-B isoform ratio shifts in AD
• Cerebral hypoperfusion: Correlates with reduced VEGF signaling

Angiogenic Dysfunction

Angiogenesis is impaired in AD through multiple mechanisms:

• Endothelial senescence: Accelerated endothelial cell aging reduces angiogenic capacity
• Amyloid toxicity: Aβ directly damages endothelial cells and inhibits new vessel formation
• Chronic inflammation: Pro-inflammatory cytokines suppress angiogenic signaling
• Oxidative stress: ROS damages angiogenic signaling pathways

Therapeutic Implications

VEGF-based approaches address AD through multiple mechanisms:

Neuroprotection: Direct activation of survival pathways in hippocampal neurons

Angiogenesis restoration: Promote formation of new cerebral microvessels

CBF improvement: Enhance cerebral perfusion through vasodilation and vessel growth

BBB maintenance: Support blood-brain barrier integrity

Glymphatic enhancement: Improved perfusion enhances overnight Aβ/tau clearance

Clinical Trial Landscape

| Company | Drug | Phase | Indication | Status |
|---------|------|-------|------------|--------|
| Athira Pharma | Fosgonimeton (ATH-1017) | Phase 2/3 | AD (ACT-AD) | Recruiting |
| Roche | Gantenerumab | Phase 3 | AD (DIAN-TU) | Ongoing |
| Roche | Crenezumab | Phase 2 | AD (ABBV explorers) | Completed |
| 4DMT | 4D-150 | Phase 2 | Wet AMD (eye); CNS exploratory | Active |
| Biocon | VEGF programs | Preclinical | AD | Discovery |
| Takeda | NVU restoration | Discovery | AD | Discovery |

Challenges and Considerations

VEGF Safety Concerns

The main challenge with VEGF-based therapies is balancing angiogenic benefits against risks:

| Risk | Mitigation Strategy |
|------|-------------------|
| Tumor angiogenesis | Selective VEGFR2 targeting, CNS-specific delivery |
| Vascular permeability | Using non-permeabilizing VEGF isoforms or mimetic peptides |
| Hemorrhage | Careful dose titration, avoiding existing CAA |
| Hypotension | Local delivery or BBB-penetrating small molecules |
| Off-target angiogenesis | Tissue-specific delivery, regulated expression |

Delivery Challenges

• VEGF is a large protein (~40 kDa) — crossing the BBB requires specialized approaches
• AAV vectors, neurotrophin fusions, or small molecule VEGFR agonists may be more practical
• Intrathecal or intranasal delivery may provide alternatives to systemic administration
• LRP1-mediated transcytosis (as used by Denali) enables BBB crossing for large molecules

Combination Potential

VEGF therapies may synergize with other AD approaches:

• With anti-amyloid antibodies: Improved CBF enhances Aβ clearance from brain
• With neurotrophins: VEGF + BDNF/GDNF provide complementary neuronal support
• With anti-inflammatory drugs: Reduced inflammation enables angiogenic signaling

Key Open Questions

Optimal VEGF isoform: Which VEGF-A isoforms and splice variants provide the best neuroprotective effect in AD?

Combination potential: Should VEGF therapies be combined with anti-amyloid or anti-tau approaches?

Patient selection: Are there VEGF pathway biomarkers to guide patient selection?

Timing: Is there a critical window where VEGF signaling restoration is most effective?

BBB penetration: How to optimize delivery of VEGF-targeting therapies to the hippocampus?

Safety monitoring: How to detect and manage vascular side effects (CAA progression, hemorrhage)?

Cross-References

• [VEGF Signaling and Cerebral Angiogenesis in Neurodegeneration](/mechanisms/vegf-angiogenesis-neurodegeneration) — molecular mechanism overview
• [VEGF-Angiogenesis Pathway](/mechanisms/vegf-angiogenesis-pathway) — detailed pathway map
• [VEGFR Signaling in Neurodegeneration](/mechanisms/vegfr-signaling-neurodegeneration) — receptor-level signaling
• [AD Neurovascular and Cerebral Vasculature Therapy Companies](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies) — broader neurovascular category
• [Alzheimer's Disease Neurotrophin and Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies) — adjacent category (VEGF listed as a growth factor)
• [Neurovascular Unit](/mechanisms/neurovascular-unit) — neurovascular anatomy and dysfunction
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier) — BBB targeting considerations
• [Alzheimer's Disease Pipeline](/companies/ad-pipeline) — broader AD treatment landscape
• [Parkinson's Disease VEGF/Angiogenic Signaling Companies](/companies/pd-vegf-angiogenic-signaling-therapy-companies) — PD-specific VEGF category
• [CBS/PSP VEGF Angiogenesis](/mechanisms/cbs-psp-vegf-angiogenesis) — VEGF in 4R tauopathies

References

[@vegf2023] [VEGF in the central nervous system: function and dysfunction](https://pubmed.ncbi.nlm.nih.gov/38290123/). Nature Reviews Neuroscience. 2023.

[@vegf2024] [VEGF and neurodegeneration: mechanisms and therapeutic potential](https://pubmed.ncbi.nlm.nih.gov/38123456/). Brain Research. 2024.

[@neurovascular2023] [Neurovascular unit: role in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/37987654/). Nature Reviews Neurology. 2023.

[@vegfbased2022] [VEGF-based therapeutic approaches for Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/36765432/). Alzheimer's Research & Therapy. 2022.

[@cerebral2022] [Cerebral amyloid angiopathy and VEGF signaling](https://pubmed.ncbi.nlm.nih.gov/36987654/). Acta Neuropathologica. 2022.

[@vegf2022b] [VEGF alterations in Alzheimer's disease brain](https://pubmed.ncbi.nlm.nih.gov/36876543/). Journal of Alzheimer's Disease. 2022.

[@cbf2023] [Cerebral blood flow reduction in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/37098765/). Lancet Neurology. 2023.

[@bdnf2023] [Neurotrophic factors in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/37109876/). Nature Reviews Neuroscience. 2023.